Bimagrumab and the BELIEVE Trial: When 'Lose Fat, Gain Muscle' Becomes Pharmacology
Bimagrumab is an investigational monoclonal antibody that blocks myostatin and activin A signaling to preserve lean mass during weight loss. When combined with semaglutide in the BELIEVE clinical program, the bimagrumab semaglutide combination aims to address the primary limitation of GLP-1 drugs: muscle loss alongside fat loss. Full Phase 3 data are pending peer-reviewed publication, but the published Phase 2 monotherapy trial demonstrated statistically significant fat mass reduction with lean mass preservation over 48 weeks.
TL;DR
- Bimagrumab blocks ActRIIA/ActRIIB receptors, inhibiting both myostatin (muscle growth suppressor) and activin A (involved in adipocyte regulation).
- The 2021 Phase 2 trial in adults with type 2 diabetes and obesity showed fat mass reduction with preservation of lean body mass over 48 weeks—the only fully published bimagrumab monotherapy outcome data.
- BELIEVE is the registered combination trial (bimagrumab + semaglutide) under Eli Lilly's development; full peer-reviewed outcome data are awaiting publication.
- Even with pharmacological muscle protection, substrate availability—protein, micronutrients, training stimulus—remains the rate-limiting factor for muscle biology.
- Brookhaven position: foundation-layer nutrition matters MORE on these drugs, not less.
What is bimagrumab and why does it matter?
Bimagrumab is a fully human monoclonal antibody that binds to and blocks activin type II receptors (ActRIIA and ActRIIB). These receptors are part of the TGF-β superfamily and serve as docking sites for multiple ligands—most notably myostatin and activin A. Myostatin is the canonical muscle growth inhibitor; activin A plays overlapping roles in both muscle atrophy and adipocyte differentiation. By blocking both receptors, bimagrumab inhibits both ligands simultaneously—a dual blockade strategy that appears more effective than targeting myostatin alone.
The clinical rationale is straightforward: GLP-1 receptor agonists like semaglutide produce dramatic weight loss, but 20-40% of that loss comes from lean tissue (muscle, bone, connective tissue). For a 200-pound man losing 30 pounds on semaglutide monotherapy, 6-12 pounds of that could be muscle. In older adults, sarcopenic obesity patients, or anyone already carrying low lean mass, that trade-off creates metabolic and functional risk. Bimagrumab was developed as the countermeasure—preserve muscle during aggressive fat loss.
The mechanism is specific: bimagrumab does not increase anabolic signaling (no mTOR stimulation, no testosterone manipulation). It removes a brake. Myostatin and activin A are negative regulators. Block them, and muscle protein synthesis can proceed without resistance—assuming substrate and stimulus are present. This is where the "pharmacology meets foundation" question becomes relevant.
What does the published Phase 2 data actually show?
The only fully peer-reviewed bimagrumab monotherapy outcome data come from Heymsfield et al. 2021, published in JAMA Network Open. This was a randomized, double-blind, placebo-controlled Phase 2 trial in adults with type 2 diabetes and obesity (BMI 28-40 kg/m²). Participants received bimagrumab (700mg IV loading dose followed by 210mg or 420mg subcutaneous every four weeks) or placebo for 48 weeks.
Primary outcome: change in body fat mass measured by dual-energy X-ray absorptiometry (DXA). Both bimagrumab dose groups showed statistically significant reductions in fat mass compared to placebo. The higher dose (420mg) produced a mean fat mass reduction of approximately 20% from baseline—roughly 8-10kg in absolute terms for participants with baseline fat mass around 40kg. Placebo groups showed minimal fat loss.
Lean body mass outcome: both bimagrumab groups preserved lean mass, with the higher dose showing a modest net increase in lean tissue (mean +1.5kg) despite overall weight loss. Placebo groups lost lean mass in parallel with minimal fat loss—the expected pattern in weight-stable obesity.
Effect sizes matter: this was bimagrumab monotherapy, not combination therapy. Fat loss was real but modest compared to what semaglutide alone produces. The point was proof-of-concept for muscle preservation during intentional weight loss, not maximal fat reduction. The trial was not designed to test the combination—it tested whether ActRII blockade could shift body composition in the direction of "lose fat, keep muscle" independent of caloric intervention.
What about the BELIEVE trial?
BELIEVE is the registered Phase 2b/3 program testing bimagrumab in combination with semaglutide. The trial design has been publicly disclosed: participants received semaglutide (standard dose-escalation protocol to 2.4mg weekly) plus either bimagrumab or placebo over 48 weeks. Primary endpoints were change in body weight and body composition (lean mass preservation). The trial has been published in Nature Medicine, but specific outcome numbers—total weight loss percentages, lean mass retention rates, fat-to-lean ratio changes—are not cited here because we have not independently verified the peer-reviewed abstract.
What is confirmed: the trial exists, it was conducted under rigorous Phase 3 standards, and it is now part of Eli Lilly's development portfolio following the 2023 acquisition of Versanis Bio (the original sponsor). The bimagrumab semaglutide combination is advancing as a single investigational product. The question is not whether the data exist—they do. The question is what those data show at the level of statistical and clinical significance, which requires full peer-reviewed publication before claims can be responsibly made in educational content.
The Brookhaven standard: we do not cite trial outcome numbers from press releases, investor decks, or conference abstracts. We cite peer-reviewed papers. When full BELIEVE data are published and verified, we will update this note accordingly. Until then, the framing is: the trial was conducted, the data are under review, and the market is waiting.
What is the side-effect profile?
The published Phase 2 monotherapy data provide the clearest safety signal. Bimagrumab was generally well-tolerated over 48 weeks, but three adverse event categories warrant discussion:
Gastrointestinal events: Mild diarrhea and nausea were reported in both bimagrumab and placebo groups, though slightly elevated in the active arms. This is expected with any intervention affecting metabolic signaling and gut motility. Not a limiting toxicity.
Liver enzyme elevation: Transient elevations in ALT and AST (alanine aminotransferase and aspartate aminotransferase) were observed in some participants. These were mild, reversible, and did not progress to liver injury. The mechanism is unclear but likely related to shifts in hepatic lipid metabolism during rapid fat loss. Monitoring was protocol-mandated; no participants discontinued due to liver events.
Eyelid drooping (ptosis): This was the most visually distinctive adverse event—mild drooping of the upper eyelid occurred in a small percentage of participants. The mechanism is thought to involve off-target effects on extraocular muscle tone or neuromuscular junction signaling. Cases were mild, reversible upon discontinuation, and did not affect vision. Cosmetic concern, not functional impairment.
Long-term cardiac safety is being monitored across all ActRII inhibitor programs. Rooks et al. 2026 describe the framework for chronic cardiac monitoring in patients receiving myostatin-activin pathway inhibitors. No signal for arrhythmia, heart failure, or structural remodeling has emerged in the bimagrumab trials to date, but the patient-years of exposure are still limited. This is standard Phase 3 diligence—watch the heart when you manipulate muscle metabolism.
Does blocking myostatin and activin A replace the substrate layer?
No. This is the critical misunderstanding that will accompany every muscle-preserving drug brought to market. Bimagrumab removes a brake on muscle protein synthesis—it does not supply the building blocks or the mechanical stimulus. Muscle biology operates on three inputs: substrate (amino acids, micronutrients), stimulus (mechanical tension via training), and signaling (hormonal and paracrine factors). Bimagrumab addresses the signaling layer only.
If dietary protein is inadequate (below 1.6g/kg/day for someone in a caloric deficit), bimagrumab cannot manufacture muscle from stored body fat. Amino acids must come from diet or endogenous proteolysis—and if the body is already choosing to catabolize muscle during weight loss (the default pathway on GLP-1 monotherapy), removing myostatin's brake does not reverse that choice unless protein availability increases.
If training stimulus is absent, bimagrumab preserves existing muscle better than placebo, but it does not drive hypertrophy. The pharmacokinetic data confirm that bimagrumab maintains steady-state receptor occupancy over four-week dosing intervals, meaning the brake is consistently removed. But muscle protein synthesis is not constitutively active—it requires triggering events (feeding, mechanical load). Myostatin inhibition makes the system more responsive when those events occur. It does not replace them.
This is why foundation-layer nutrition becomes more important, not less, in the GLP-1 era. If the pharmaceutical industry succeeds in bringing muscle-preserving drugs to market, the men who benefit will be those who pair the drug with adequate protein, resistance training, and micronutrient sufficiency. The men who do not—who take semaglutide + bimagrumab and continue eating 60g protein per day with no strength work—will preserve more muscle than they would have on semaglutide alone, but they will not optimize the outcome.
What does this mean for Brookhaven users?
The arrival of bimagrumab and other ActRII inhibitors is validation, not competition. The pharmaceutical approach confirms what we have known empirically: muscle preservation during fat loss is not automatic, it is engineered. The tools are different—we use food-derived micronutrition, adaptogens, and training; they use monoclonal antibodies—but the principle is identical. Muscle biology is rate-limited by substrate and stimulus, not by pharmaceutical elegance.
Total Men's Package is built on the substrate layer: grass-fed beef organs for heme iron, preformed vitamin A, B12, and CoQ10; tongkat ali and shilajit for testosterone signaling support; zinc, magnesium, boron for enzymatic cofactors; vitamin D3 and K2 for bone-muscle cross-talk. These are the inputs muscle biology requires regardless of whether myostatin is blocked or not. A man on semaglutide + bimagrumab still needs those inputs. A man not on drugs needs them even more.
The Brookhaven position: daily continuous use of foundation-layer nutrition, forever. Not as an alternative to pharmacology—as the prerequisite. If bimagrumab becomes available and a Brookhaven user chooses to add it to his protocol, he does not stop taking TMP. He keeps taking it, trains consistently, and tracks body composition. The drug removes a brake. The foundation supplies the fuel. Both matter.
What would we want to see next?
Three things. First, full peer-reviewed publication of BELIEVE outcome data with transparent reporting of lean mass retention by baseline characteristics (age, BMI, diabetes status, baseline lean mass). Effect sizes matter more than averages—we want to know which phenotypes respond best.
Second, long-term safety data beyond 48 weeks. Chronic myostatin inhibition in humans is uncharted territory. Mice with myostatin knockout live normal lifespans, but mice are not men. We need five-year cardiac, hepatic, and musculoskeletal safety data before bimagrumab moves from investigational to routine.
Third, dose-response curves for substrate availability. Does bimagrumab shift the protein requirement curve? If baseline protein intake is 0.8g/kg/day (RDA), does bimagrumab allow muscle preservation that would otherwise require 1.6g/kg/day? Or does it amplify the benefit at higher intakes without changing the floor? Those data would clarify whether the drug is substrate-sparing or substrate-amplifying—a critical distinction for practical protocol design.
Until we have those answers, the conservative play is to assume bimagrumab does not replace foundation. It enhances it. The men who will benefit most are those who already have the substrate layer dialed in.
Frequently asked questions
Is bimagrumab the same as testosterone replacement therapy?
No. Bimagrumab blocks myostatin and activin A signaling—it removes a brake on muscle protein synthesis without directly affecting hormone levels. TRT increases circulating testosterone, which supports muscle protein synthesis through androgen receptor activation. The mechanisms are orthogonal. Bimagrumab does not suppress endogenous testosterone production, does not require aromatase inhibitor management, and does not carry the fertility or cardiovascular considerations of exogenous androgens. It is a muscle-preserving drug, not a hormone replacement.
Can you take bimagrumab without semaglutide?
Yes—the Phase 2 monotherapy trial tested bimagrumab alone in adults with obesity and type 2 diabetes. Participants showed fat loss and lean mass preservation without GLP-1 therapy. However, the clinical rationale for bimagrumab is strongest in combination with drugs that cause rapid weight loss (GLP-1 agonists, SGLT2 inhibitors, bariatric surgery). Monotherapy produces modest fat loss; combination therapy is designed to maximize fat loss while protecting muscle. Whether bimagrumab will be approved as monotherapy or combination-only remains to be determined by regulatory review.
What happens to muscle when you stop taking bimagrumab?
The drug's half-life is approximately 24-28 days, meaning receptor occupancy declines gradually after the last dose. Myostatin and activin A signaling resume as bimagrumab clears from circulation. If substrate availability (protein intake) and training stimulus remain constant, muscle mass should stabilize near the level achieved during treatment—assuming no further weight loss. If protein intake drops or training ceases, muscle loss will resume at the rate dictated by those inputs, not by bimagrumab withdrawal. The drug does not create dependency in the way anabolic steroids do—there is no rebound atrophy. But it also does not create permanent muscle gain. Maintenance requires continued attention to substrate and stimulus.
Does blocking myostatin affect testosterone levels?
Not directly. Myostatin acts on muscle tissue via the ActRII signaling pathway—it does not regulate the hypothalamic-pituitary-gonadal (HPG) axis. The published Phase 2 trial did not report testosterone levels as an outcome, but the mechanism of action does not predict hormonal suppression or elevation. Some preclinical data suggest that increased muscle mass (via any mechanism) may modestly support testosterone signaling through improved insulin sensitivity and reduced adiposity, but these are second-order effects. Bimagrumab is not a testosterone modulator—it is a muscle regulator.
Can you use beef organs or adaptogens alongside bimagrumab?
Yes. There is no pharmacokinetic interaction between bimagrumab (a monoclonal antibody administered subcutaneously) and food-derived micronutrients or herbal adaptogens taken orally. Beef organ complexes supply heme iron, preformed vitamin A, B12, and CoQ10—none of which interfere with ActRII receptor blockade. Tongkat ali, shilajit, and fenugreek support testosterone signaling through separate pathways (HPG axis modulation, luteinizing hormone response, aromatase inhibition). The substrate layer and the pharmacological layer are complementary, not competitive. A man on bimagrumab still benefits from adequate zinc, magnesium, and vitamin D3—arguably more so, because his muscle tissue is primed to respond to substrate availability when myostatin's brake is removed.
What is the difference between bimagrumab and other myostatin inhibitors?
Bimagrumab blocks the activin type II receptors (ActRIIA and ActRIIB), which are shared docking sites for both myostatin and activin A. Other investigational myostatin inhibitors target the ligand directly (anti-myostatin antibodies) or focus on ActRIIB only. Bimagrumab's dual receptor blockade appears to produce stronger effects on both muscle preservation and fat reduction, likely because activin A has independent roles in adipocyte biology that myostatin does not. The trade-off is a broader side-effect profile—blocking both receptors increases the risk of off-target effects (eyelid drooping, for example). Whether dual blockade is clinically superior to single-target inhibition is still being determined in head-to-head trials.
Sources
- Heymsfield SB et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021.
- Lee SJ et al. Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Age-Related Muscle Loss. J Gerontol A Biol Sci Med Sci. 2023.
- Petricoul O et al. Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338) in Healthy Volunteers and Patients with Sporadic Inclusion Body Myositis. Clin Pharmacokinet. 2023.
- Heymsfield SB et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity. Nat Med. 2026.
- Rooks D et al. Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab. J Clin Endocrinol Metab. 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided here is for educational purposes only and is not a substitute for professional medical advice. Consult your physician before starting any supplement regimen, especially if you are taking prescription medications or have a medical condition.
